ClinicalTrials.gg

Program

TQB2252

A development code. Also written as “TQB2252 injection”.

In Sino Biopharmaceutical's pipeline, PD-1/LAG-3复方. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 1, since Oct 17, 20241 company-led study, 1 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Oct 17, 2024Oct 17, 2024Nov 2026phase 1 · NCT06649656
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2252, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2024First study: phase 1 study in Advanced CancersFirst studyNCT06649656 · 100 planned · China

Ahead

  1. Nov 2026Primary completion: phase 1 study in Advanced CancersNCT06649656

TargetBeta

“PD-1/LAG-3复方”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-PD-1/LAG-3 Bispecific Antibody AK129ruleAkesophase 24

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06649656Advanced Cancers · China1Not yet recruitingNov 2026100

How it is read

Names in the registry

  • “TQB2252 injection”, 1 entry

Codes read as this program: TQB2252.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.